{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:16:22Z","timestamp":1791411382419,"version":"4.3.3"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T00:00:00Z","timestamp":1449619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Intensive chemotherapy regimens containing cytarabine have substantially improved remission durability and overall survival in younger adults with mantle cell lymphoma (<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>). However, there have been no long\u2010term follow\u2010up results for patients treated with these regimens. We present long\u2010term survival outcomes from a pivotal phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> trial of rituximab, hyper\u2010fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with methotrexate and cytarabine (R\u2010<jats:styled-content style=\"fixed-case\">HCVAD<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">MA<\/jats:styled-content>)<jats:bold>.<\/jats:bold> At 15\u00a0years of follow\u2010up (median: 13\u00b74\u00a0years), the median failure\u2010free survival (<jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content>) and overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) for all patients was 4\u00b78\u00a0years and 10\u00b77\u00a0years, respectively. The <jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content> seems to have plateaued after 10\u00a0years, with an estimated 15\u2010year <jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content> of 30% in younger patients (\u226465\u00a0years). Patients who achieved complete response (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>) after 2 cycles had a favourable median <jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content> of 8\u00b78\u00a0years. Six patients developed myelodysplastic syndrome\/acute myeloid leukaemia (<jats:styled-content style=\"fixed-case\">MDS<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">AML<\/jats:styled-content>) whilst in first <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>. The 10\u2010year cumulative incidence of <jats:styled-content style=\"fixed-case\">MDS<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">AML<\/jats:styled-content> of patients in first remission was 6\u00b72% (95% confidence interval: 2\u00b75\u201312\u00b72%). In patients with newly diagnosed <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>, R\u2010<jats:styled-content style=\"fixed-case\">HCVAD<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">MA<\/jats:styled-content> showed sustained efficacy, with a median <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> exceeding 10\u00a0years in all patients and freedom from disease recurrence of nearly 15\u00a0years in almost one\u2010third of the younger patients (\u226465\u00a0years).<\/jats:p>","DOI":"10.1111\/bjh.13796","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T23:00:42Z","timestamp":1449788442000},"page":"80-88","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Rituximab plus hyper\u2010<scp>CVAD<\/scp> alternating with <scp>MTX<\/scp>\/Ara\u2010C in patients with newly diagnosed mantle cell lymphoma: 15\u2010year follow\u2010up of a phase <scp>II<\/scp> study from the <scp>MD<\/scp> Anderson Cancer Center"],"prefix":"10.1111","volume":"172","author":[{"given":"Dai","family":"Chihara","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-2337","authenticated-orcid":false,"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick B.","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[{"name":"Division of Hematology Thomas Jefferson University Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"Lymphoma Service Memorial Sloan Kettering Cancer Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center Hackensack University Medical Center Hackensack NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"Haematology Auxilio Mutuo Cancer Centre San Juan Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Romaguera","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,12,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559930"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402272"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt070"},{"key":"e_1_2_7_5_1","first-page":"2971","article-title":"Clinicopathologic features, management and outcomes of blastoid variant (BV) of mantle cell lymphoma (MCL): a nebraska lymphoma study group (NLSG) experience","volume":"124","author":"Bhatt V.R.","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.656628"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12659"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09174.x"},{"key":"e_1_2_7_14_1","first-page":"425","article-title":"Rituximab and DHAP followed by intensive therapy with autologous stem\u2010cell transplantation as first\u2010line therapy for mantle cell lymphoma","volume":"91","author":"Guibert S.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_15_1","first-page":"623","article-title":"Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA\u2010C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the european mantle cell lymphoma network (MCL net)","volume":"120","author":"Hermine O.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1288"},{"key":"e_1_2_7_18_1","volume-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","author":"Jaffe E.","year":"2001"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-369629"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08958.x"},{"key":"e_1_2_7_24_1","unstructured":"NCCN. (2015)NCCN Clinical Practice Guidelines in Oncology. Non\u2010Hodgkin's Lymphomas (Version 2. 2015) Vol. 2015.National Comprehensive Cancer Network.Fort Washington PA USA. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf."},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08228.x"},{"key":"e_1_2_7_27_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.","year":"2008"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9777"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05716.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23615"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.568"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13796","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T04:02:47Z","timestamp":1696305767000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,9]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1111\/bjh.13796"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13796","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,9]]},"assertion":[{"value":"2015-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-08-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}